Memantine extended release (28 mg once daily): A review of its use in Alzheimer's disease

Drugs

Volumn 75, Issue 8, 2015, Pages 887-897

  Plosker, Greg L ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; DONEPEZIL PLUS MEMANTINE; HYDROCHLOROTHIAZIDE; MEMANTINE; PLACEBO; TRIAMTERENE; AMINO ACID RECEPTOR BLOCKING AGENT; DELAYED RELEASE FORMULATION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ABDOMINAL PAIN; ALZHEIMER DISEASE; BACKACHE; BEHAVIOR CHANGE; COGNITION; COMBINATION CHEMOTHERAPY; COMMUNICATION SKILL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; LANGUAGE ABILITY; MONOTHERAPY; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SOMNOLENCE; VOMITING; ANTAGONISTS AND INHIBITORS; DELAYED RELEASE FORMULATION; DRUG COMBINATION;

ALZHEIMER DISEASE; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84930179409     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0400-3     Document Type: Review

References (45)

1. Alzheimer's Association. 2014 Alzheimer's disease facts and figures. http://www.alz.org/downloads/Facts-Figures-2014.pdf. Accessed 25 Nov 2014.
2. Alzheimer's Disease International. The global impact of dementia 2013-2050. http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf. Accessed 25 Nov 2014.
3. Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013;369(24):2275-7.
4. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.
5. McKeage K. Memantine. CNS Drugs. 2009;23(10):881-97.
6. Namenda (memantine hydrochloride): US prescribing information. 2013. http://www.frx.com/pi/namenda-pi.pdf. Accessed 15 Apr 2015.
7. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333-41.
8. van Dyck CH, Tariot PN, Meyers B, et al. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21(2):136-43.
9. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
10. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-24.
11. Atri A, Molinuevo JL, Lemming O, et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.
12. Hendrix S, Ellison N, Stanworth S, et al. Evidence for an additive effect of memantine and donepezil: consistent conclusions from DOMINO-AD study and memantine clinical trial program (poster). In: 7th clinical trials conference on Alzheimer's disease; 2014.
13. Namenda XR (memantine hydrochloride) extended release capsules: US prescribing information. 2014. http://www.frx.com/pi/namendaxr-pi.pdf. Accessed 15 Apr 2015.
14. Lyseng-Williamson KA, McKeage K. Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU. Drugs Aging. 2013;30(1):51-8.
15. Makino KM, Porsteinsson AP. Memantine: a treatment for Alzheimers disease with a new formulation. Aging Health. 2011;7(3):349-62.
16. Ong WY, Tanaka K, Dawe GS, et al. Slow excitotoxicity in Alzheimer's disease. J Alzheimers Dis. 2013;35(4):643-68.
17. Gilling KE, Jatzke C, Parsons CG. Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. Neuropharmacology. 2007;53(3):415-20.
18. Volbracht C, van Beek J, Zhu C, et al. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity. Eur J Neurosci. 2006;23(10):2611-22.
19. Parsons CG, Danysz W, Dekundy A, et al. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013;24(3):358-69.
20. Pope LE, Schoedel KA, Bartlett C, et al. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012;32(8):e1-15.
21. Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013;27(6):469-78.
22. Tocco M, Hendrix S, Miller M, et al. Clinical benefits of extended-release memantine (28 mg, once daily) as a function of disease severity in people with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial (abstract no. P3-271 plus poster). Alzheimers Dement. 2013;9(4 Suppl.):P655.
23. Graham S, Hendrix S, Miller M, et al. Response across multiple outcome measures in a randomized trial of extended-release memantine (28 mg once daily) in patients with moderate-to-severe Alzheimer's disease (abstract no. P3-386 plus poster). Alzheimers Dement. 2012;8(4 Suppl.):P591.
24. Atri A, Tocco M, Hendrix S, et al. Cumulative benefits of extended-release memantine (28 mg, once daily) across clinical domains in patients with moderate to severe alzheimer's disease: an area under the curve analysis (abstract no. NR 16 plus poster). Am J Geriatr Psychiatry. 2014;22(3, Suppl.):S120-S1.
25. Tocco M, Hendrix S, Miller M, et al. Effects of extended-release memantine (28 mg, once daily) on cognitive domains in patients with moderate to severe Alzheimer's disease: post hoc analysis of a randomized trial (abstract no. 26 plus poster). Consult Pharm. 2011;26(10):750.
26. Tocco M, Hendrix S, Miller ML, et al. Sustained cognitive improvement with extended-release memantine (28 mg, once daily) in moderate to severe Alzheimer's disease (abstract no. M1116 plus poster). Ann Neurol. 2012;72(Suppl. 16):S42.
27. Graham SM, Hendrix S, Miller ML, et al. Extended-release memantine (28 mg, once daily) provides behavioral benefits across a wide range of disease severity in patients with moderate to severe Alzheimer's disease: post hoc analysis from a randomized trial (abstract no. NR 16 plus poster). Am J Geriatr Psychiatry. 2013;21(3):S139.
28. Cummings J, Hendrix S, Miller M, et al. Extended-release memantine (28 mg, once daily) and sustained behavioral improvement: post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease (abstract no. P04.197 plus poster). Neurology. 2012;78.
29. Tocco M, Hendrix S, Miller ML, et al. Effects of extended-release memantine (28 mg, once daily) on language and communication abilities in patients with moderate to severe Alzheimer's disease (abstract no. M1156 plus poster). Ann Neurol. 2012;72(Suppl. 16):S52-3.
30. Graham SM, Hendrix S, Miller ML, et al. Efficacy of extended-release memantine (28 mg, once daily): post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease (abstract no. 27 plus poster). Consult Pharm. 2011;26(10):750.
31. Tocco M, Hendrix S, Miller ML, et al. Effects of extended-release memantine (28 mg, once daily) on individual activities of daily living in patients with moderate to severe Alzheimer's disease: post hoc factor analysis of a randomized trial (abstract no. 20 plus poster). Consult Pharm. 2011;26(10):747.
32. Grossberg G, Alva G, Hendrix S, et al. Efficacy and tolerability of memantine extended release added to stable donepezil regimen in individuals with moderate to severe Alzheimer's disease: subset analysis of a randomized clinical trial (abstract no. P1-370 plus poster). Alzheimers Dement. 2014;10(4):P450.
33. Hendrix S, Ellison N, Pejovic V, et al. Adding memantine to cholinesterase inhibitor treatment stabilizes or improves low to moderate agitation in patients with moderate to severe Alzheimer's disease: post hoc analysis of five randomized trials (poster no. LB 54). In: Annual meeting of the American Association for Geriatric Psychiatry. 2015.
34. Hendrix S, Ellison N, Pejovic V, et al. Adding memantine to stable cholinesterase inhibitor therapy in patients with moderate to severe Alzheimer's disease is associated with improvement in various neuropsychiatric symptoms: a pooled analysis (poster no. LB 55). In: Annual meeting of the American Association for Geriatric Psychiatry. 2015.
35. Hendrix S, Ellison N, Pejovic V, et al. Effects of add-on memantine on daily functioning in patients with moderate to severe Alzheimer's disease receiving stable donepezil treatment (poster). In: 12th international conference on Alzheimer's and Parkinson's Diseases. 2015.
36. Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-8.
37. Singh I, Grossberg GT. High-dose donepezil or memantine: next step for Alzheimer's disease? Current Psychiatry. 2012;11(6):20.
38. Exelon Patch (rivastigmine transdermal system): US prescribing information. 2015. http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf. Accessed 15 Apr 2015.
39. Actavis and Adamas announce FDA approval of Namzaric™, a fixed-dose combination of memantine extended-release and donepezil hydrochloride. 2014. http://www.prnewswire.com/news-releases/actavis-and-adamas-announce-fda-approval-of-namzaric-a-fixed-dose-combination-of-memantine-extended-release-and-donepezil-hydrochloride-300013883.html. Accessed 12 Jan 2015.
40. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open. 2012;2(3):e000917.
41. Thibault CSL, Stillman IO, Chen S, et al. Cost-effectiveness of memantine extended release for treatment of moderate-to-severe Alzheimer's disease in the United States (abstract no. P2-320 plus poster). Alzheimers Dement. 2014;10(4 Suppl.):P596-P7.
42. Zhu CW, Livote EE, Scarmeas N, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimers Dement. 2013;9(6):733-40.
43. Atri A, Shaughnessy LW, Locascio JJ, et al. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.
44. Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(6):600-7.
45. Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1(2):7.